State coverage
Montana Medicaid and GLP-1 coverage
Medicaid, for obesity: Other diagnoses only. The conditions and the appeal deadline are in the summary below.
At a glance
- Medicaid, for obesity
- The standard drug list never names Wegovy or Zepbound; a separate pathway covers each for a non-obesity reason.
Montana is the state where reading only the standard drug list would get you the wrong answer. Two editions were checked eight months apart — the one revised January 15, 2026 and the one revised July 30, 2026 — and neither names Wegovy, Zepbound or Saxenda anywhere across their 33 pages, and neither carries a weight-loss or anti-obesity drug class at all. The diabetes GLP-1 class lists only Ozempic, Trulicity, Victoza and Mounjaro, each restricted to a type 2 diabetes diagnosis with a required trial of two preferred agents first.
That absence would read as a flat no if the drug list were the only document available. It is not the only document. A quarterly newsletter from Mountain Pacific Quality Health, the contractor that runs Montana's drug prior-authorization desk, lays out a separate pathway for members without diabetes: Wegovy for a liver condition called MASH or for reducing cardiovascular risk, and Zepbound for obstructive sleep apnea. Neither drug is covered for weight loss or obesity as such — the newsletter says so in those words, twice.
The standard drug list is silent on this because these approvals route through their own prior authorization forms rather than through ordinary drug-list placement, and the newsletter is currently the clearest public statement of what those forms will approve. The state's general pharmacy provider manual supplies the legal floor underneath both documents: drugs for weight reduction are excluded from coverage outright.
One host could not be verified at all. Montana's official rules website, rules.mt.gov, is a JavaScript application that returned the identical 894-byte page shell for every URL tried on 2026-09-03 — a real rule number and a nonsense one alike, byte for byte. So nothing on this page rests on that site, and the Administrative Rules of Montana provision that presumably states this exclusion in the state's own regulatory language was not read. That is a gap in what we could open, not a finding about what the rule says.
What we could verify for Montana
Neither the January 15, 2026 nor the July 30, 2026 edition of the Montana Healthcare Programs Preferred Drug List names Wegovy, Zepbound or Saxenda anywhere in its 33 pages, and neither carries a weight-loss or anti-obesity drug class. The "DIABETES: GLP-1/GIP AND COMBOS" class lists only "Ozempic," "Trulicity" and "Victoza" as preferred and "Mounjaro," "Bydureon BCISE," "Rybelsus" and generic exenatide and liraglutide as non-preferred, each requiring a "Trial of 2 preferred agents for 6 months each" and a type 2 diabetes diagnosis.
Montana Department of Public Health and Human Services, Montana Healthcare Programs Preferred Drug List, effective July 2026 · source
The state's quarterly drug-utilization newsletter states the non-diabetes pathway directly: "Wegovy® is semaglutide, the same active ingredient as Ozempic®, but is not approved for and is not covered for type 2 diabetes. It has an FDA indication but is not covered for weight loss or obesity by Montana Healthcare Programs. Wegovy® injection is covered in adults for diagnoses: Noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis. Reduction of risk of major adverse cardiovascular events (MACE) in adults with established cardiovascular disease (CVD) and either obesity or overweight."
Mountain Pacific Quality Health, Montana's Medicaid drug prior-authorization contractor, Montana Healthcare Programs DUR Newsletter, effective March 2026 · source
The same newsletter states the Zepbound pathway: "Zepbound® is tirzepatide, the same active ingredient as Mounjaro®, but is not approved for and will not be covered for type 2 diabetes. It has an FDA indication for but is not covered for weight loss or obesity by Montana Healthcare Programs. Zepbound® is covered in adults for: A diagnosis made by a sleep specialist of obstructive sleep apnea (OSA) with an apnea-hypopnea index (AHI) greater or equal to 15 while on current positive airway pressure treatment (either CPAP or BiPAP)... Body mass index (BMI) at time of sleep study was greater than or equal to 30 kg/m2, AND Member has been on PAP continuously for at least six months prior to request."
Mountain Pacific Quality Health, Montana Healthcare Programs DUR Newsletter, effective March 2026 · source
The state's Prescription Drug Program Manual lists drugs prescribed "For weight reduction" among what Medicaid does not cover, alongside drugs prescribed to promote fertility, for erectile dysfunction, or for cosmetic purposes or hair growth.
Montana Department of Public Health and Human Services, Prescription Drug Program Manual, Covered Products chapter, effective July 2026 · source
Montana's Medicaid fair-hearing policy sets the filing window: "The hearing request must be in writing and the Department must receive it within 90 days of the date the adverse action notice is mailed; the claimant's signature is not required." The chart accompanying this rule states that benefits continue "if FH requested before effective date OR within 10 days of adverse action notice (when timely notice not sent)."
Montana Department of Public Health and Human Services, Combined Medicaid Assistance Manual, CMA 1505-1 (Fair Hearings, Administrative Reviews, and Appeals), effective July 2016 · source
Montana is one of 33 states whose Medicaid gives the same answer: weight loss excluded; heart, liver or sleep apnea can qualify. Montana Medicaid's rule doesn't reach a job-based plan or Medicare. If you have one of those, read employer plans or Medicare Part D instead, and compare Montana with the rest in the coverage matrix.
If you work for the State of Montana
State employees aren't on Medicaid, so the answer above isn't yours. Your plan is the one the state buys for its workers: State of Montana Benefit Plan (State Plan). Its pharmacy benefit runs through Navitus Health Solutions.
Weight-loss drugs excluded
The State Plan's drug benefit excludes drugs prescribed for weight management, and the medical plan excludes drugs for weight reduction or control. What it offers instead is a $200 incentive for finishing WW, Healthy for Life or a Diabetes Prevention Program and losing 10% of your weight.
The prescription drug appendix says "Prescription drugs or supplies in the following categories are specifically excluded:" and the list includes "Drugs prescribed for weight management."
State of Montana, Wrap Plan Document for Medical, Prescription Drug, Dental, Vision, Health Centers, and Wellness Program Benefits, Appendix B (Prescription Drug Benefits), effective January 2026 · source
The medical plan also excludes "Services, supplies, drugs and devices for weight reduction or weight control. This exclusion does not include intensive behavioral dietary counseling when services are provided by a Physician, Physician Assistant - Certified or Advanced Practice Registered Nurse."
State of Montana, Wrap Plan Document for Medical, Prescription Drug, Dental, Vision, Health Centers, and Wellness Program Benefits, effective January 2026 · source
"Eligible Members may earn an annual $200 Healthy Weight Incentive for completing Weight Watchers, Healthy for Life Self-Study, or a Diabetes Prevention Program." To claim it you must "Submit proof of 10% weight loss."
State of Montana, Wrap Plan Document for Medical, Prescription Drug, Dental, Vision, Health Centers, and Wellness Program Benefits, Healthy Weight Incentive Program, effective January 2026 · source
"Navitus Health Solutions (Navitus) is the pharmacy benefit manager and processes pharmacy claims for the State Plan."
Montana Department of Administration, Health Care & Benefits Division, Prescription Drug Plan · source
If the appeal fails, or you cannot wait
Montana Medicaid excludes weight loss but can still approve these drugs for another approved use, set out in the facts above. If none of those applies to you, cash-pay telehealth is the fallback: you pay the whole cost yourself, with no Medicaid help.
These companies pay us a commission if you start care through the links below. That is how this site is funded, and it does not change what is written above. How we pay for this.
| Company | What we found on its own site |
|---|---|
| PartnerStrut HealthCheck availability | A telehealth storefront where weight loss is one of six categories. No GLP-1 price is published on the page our link opens. |
| PartnerRxSpan MDCheck availability | Multi-category telehealth that promises transparent pricing, then publishes no GLP-1 price on the page our link opens. |
| PartnerSnagRxCheck availability | Compounded semaglutide at $69 a month and tirzepatide at $119, the same at every dose, with no membership. Both are countdown sale prices, marked down from $299 and $399. Not available in Louisiana. |
| PartnerSkinnyRxCheck availability | Compounded semaglutide and tirzepatide injections at $99 for the first month, tablets at $149 and $199. No second-month price is printed for any of them. |
| PartneryourEraCheck availability | Compounded semaglutide at $79.20 a month and tirzepatide at $159.20. Both are six-month-plan prices, and the plan carries a six-month commitment. |
| PartnerbmiMDCheck availability | Compounded semaglutide from $119 a month and tirzepatide from $179. Both are limited-time sale prices, marked down from $228.60 and $349.20. |
All 21 companies, with what we found on each →
Prices in those notes were read from each company's own site in September 2026, and they change often. Check the current number before you buy.
Where this comes from
- Montana Department of Public Health and Human Services, Montana Healthcare Programs Preferred Drug List, effective July 2026 — medicaidprovider.mt.gov/docs/pharmacy/2026/July2026PreferredDrugList.pdf
- Mountain Pacific Quality Health, Montana's Medicaid drug prior-authorization contractor, Montana Healthcare Programs DUR Newsletter, effective March 2026 — Open the document
- Montana Department of Public Health and Human Services, Prescription Drug Program Manual, Covered Products chapter, effective July 2026 — medicaidprovider.mt.gov/manuals/prescriptiondrugprogrammanual
- Montana Department of Public Health and Human Services, Combined Medicaid Assistance Manual, CMA 1505-1 (Fair Hearings, Administrative Reviews, and Appeals), effective July 2016 — dphhs.mt.gov/assets/hcsd/mamanual/CMA1505-1July012016.pdf